BCLI Quote, Financials, Valuation and Earnings

Lifeward has a net margin of -- compared to Brainstorm Cell Therapeutics's net margin of -96.03%. Brainstorm Cell Therapeutics's return on equity of -- beat Lifeward's return on equity of -92.59%.

Brainstorm Cell Therapeutics has a consensus price target of $15.78, signalling upside risk potential of 1215.28%. On the other hand Lifeward has an analysts' consensus of $8.67 which suggests that it could grow by 1071.17%. Given that Brainstorm Cell Therapeutics has higher upside potential than Lifeward, analysts believe Brainstorm Cell Therapeutics is more attractive than Lifeward.

Brainstorm Cell Therapeutics has a beta of 0.223, which suggesting that the stock is 77.719% less volatile than S&P 500. In comparison Lifeward has a beta of 0.016, suggesting its less volatile than the S&P 500 by 98.425%.

Brainstorm Cell Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifeward offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainstorm Cell Therapeutics pays -- of its earnings as a dividend. Lifeward pays out -- of its earnings as a dividend.

Brainstorm Cell Therapeutics quarterly revenues are --, which are smaller than Lifeward quarterly revenues of $5M. Brainstorm Cell Therapeutics's net income of -$2.9M is higher than Lifeward's net income of -$4.8M. Notably, Brainstorm Cell Therapeutics's price-to-earnings ratio is -- while Lifeward's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainstorm Cell Therapeutics is -- versus 0.27x for Lifeward. Usually stocks with elevated PS ratios are considered overvalued.

Mersana Therapeutics has a net margin of -- compared to Brainstorm Cell Therapeutics's net margin of -875.93%. Brainstorm Cell Therapeutics's return on equity of -- beat Mersana Therapeutics's return on equity of -533.43%.

Brainstorm Cell Therapeutics has a consensus price target of $15.78, signalling upside risk potential of 1215.28%. On the other hand Mersana Therapeutics has an analysts' consensus of $4.29 which suggests that it could grow by 1163.1%. Given that Brainstorm Cell Therapeutics has higher upside potential than Mersana Therapeutics, analysts believe Brainstorm Cell Therapeutics is more attractive than Mersana Therapeutics.

Brainstorm Cell Therapeutics has a beta of 0.223, which suggesting that the stock is 77.719% less volatile than S&P 500. In comparison Mersana Therapeutics has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.338%.

Brainstorm Cell Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mersana Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainstorm Cell Therapeutics pays -- of its earnings as a dividend. Mersana Therapeutics pays out -- of its earnings as a dividend.

Brainstorm Cell Therapeutics quarterly revenues are --, which are smaller than Mersana Therapeutics quarterly revenues of $2.8M. Brainstorm Cell Therapeutics's net income of -$2.9M is higher than Mersana Therapeutics's net income of -$24.1M. Notably, Brainstorm Cell Therapeutics's price-to-earnings ratio is -- while Mersana Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainstorm Cell Therapeutics is -- versus 1.23x for Mersana Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

PAVmed has a net margin of -- compared to Brainstorm Cell Therapeutics's net margin of -1105.92%. Brainstorm Cell Therapeutics's return on equity of -- beat PAVmed's return on equity of --.

Brainstorm Cell Therapeutics has a consensus price target of $15.78, signalling upside risk potential of 1215.28%. On the other hand PAVmed has an analysts' consensus of $11.50 which suggests that it could grow by 1900%. Given that PAVmed has higher upside potential than Brainstorm Cell Therapeutics, analysts believe PAVmed is more attractive than Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics has a beta of 0.223, which suggesting that the stock is 77.719% less volatile than S&P 500. In comparison PAVmed has a beta of 1.060, suggesting its more volatile than the S&P 500 by 5.988%.

Brainstorm Cell Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainstorm Cell Therapeutics pays -- of its earnings as a dividend. PAVmed pays out -- of its earnings as a dividend.

Brainstorm Cell Therapeutics quarterly revenues are --, which are smaller than PAVmed quarterly revenues of $8K. Brainstorm Cell Therapeutics's net income of -$2.9M is lower than PAVmed's net income of $19M. Notably, Brainstorm Cell Therapeutics's price-to-earnings ratio is -- while PAVmed's PE ratio is 0.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainstorm Cell Therapeutics is -- versus 8.46x for PAVmed. Usually stocks with elevated PS ratios are considered overvalued.

Protagenic Therapeutics has a net margin of -- compared to Brainstorm Cell Therapeutics's net margin of --. Brainstorm Cell Therapeutics's return on equity of -- beat Protagenic Therapeutics's return on equity of --.

Brainstorm Cell Therapeutics has a consensus price target of $15.78, signalling upside risk potential of 1215.28%. On the other hand Protagenic Therapeutics has an analysts' consensus of -- which suggests that it could grow by 6392.75%. Given that Protagenic Therapeutics has higher upside potential than Brainstorm Cell Therapeutics, analysts believe Protagenic Therapeutics is more attractive than Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics has a beta of 0.223, which suggesting that the stock is 77.719% less volatile than S&P 500. In comparison Protagenic Therapeutics has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.562%.

Brainstorm Cell Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagenic Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainstorm Cell Therapeutics pays -- of its earnings as a dividend. Protagenic Therapeutics pays out -- of its earnings as a dividend.

Brainstorm Cell Therapeutics quarterly revenues are --, which are smaller than Protagenic Therapeutics quarterly revenues of --. Brainstorm Cell Therapeutics's net income of -$2.9M is lower than Protagenic Therapeutics's net income of -$1.4M. Notably, Brainstorm Cell Therapeutics's price-to-earnings ratio is -- while Protagenic Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainstorm Cell Therapeutics is -- versus 0.13x for Protagenic Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.